Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Breast Cancer Treatment Based on Organ-like Culture
- Conditions
- Interventions
- Drug: TrastuzumabDrug: Doxorubicin HydrochlorideDrug: Epirubicin hydrochlorideDrug: FluorouracilDrug: PaclitaxelDrug: GemcitabineDrug: CisplatinDrug: Recombinant Human EndostatinDrug: Pirarubicin hydrochlorideDrug: PyrrolidineDrug: IxabepiloneDrug: Tamoxifen citrateDrug: Vinorelbine tartrateDrug: CarboplatinDrug: MethotrexateDrug: Eribulin mesylateDrug: Toremifene citrateDrug: AnastrozoleDrug: LetrozoleDrug: ExemestaneDrug: FulvestrantDrug: OlaparibDrug: BevacizumabDrug: Apatinib mesylateDrug: PattozumabDrug: CapecitabineDrug: Ear particlesDrug: Aidi InjectionDrug: Cyclophosphamide
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT03925233
- Locations
- 🇨🇳
JingSu, Xi'an, Shaanxi, China
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- National Cancer Center, Japan
- Target Recruit Count
- 36
- Registration Number
- NCT03914443
- Locations
- 🇯🇵
National Cancer Center Hospital, Tokyo, Japan
IMRT With Carboplatin Versus IMRT With Carboplatin and Fluorouracil for Eldly Esophageal Cancer Patients
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 264
- Registration Number
- NCT03910634
- Locations
- 🇨🇳
SYSU Cancer Center, Guangzhou, Guangdong, China
Efficacy and Safety of XEN® Gel Stent and Post-operative Management in Patients With Open Angle Glaucoma
- Conditions
- Interventions
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Wroclaw Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT03904381
- Locations
- 🇵🇱
Department of Ophthalmology, Wrocław, Poland
Pan Tumor Rollover Study
- Conditions
- Interventions
- Drug: NivolumabDrug: LeucovorinDrug: Nivolumab + RelatlimabDrug: RegorafinibDrug: CapecitabineDrug: PemetrexedDrug: EnzalutamideDrug: SunitinibDrug: PembrolizumabDrug: RelatlimabDrug: TemozolomideDrug: RucaparibDrug: IpilimumabDrug: DaratumumabDrug: FluorouracilDrug: CabozantinibDrug: TrametinibDrug: BevacizumabDrug: Oxaliplatin
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1500
- Registration Number
- NCT03899155
- Locations
- 🇧🇷
Local Institution - 0260, Belo Horizonte, Minas Gerais, Brazil
🇨🇳Harbin Medical University - Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Local Institution - 0172, Changsha, Hunan, China
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT03883919
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT03881111
- Locations
- 🇨🇳
Peking Union Medical College Hospital ( Site 0123), Beijing, Beijing, China
🇨🇳Guangdong General Hospital ( Site 0103), Guangzhou, Guangdong, China
🇨🇳The Affiliated Tumour Hospital of Harbin Medical University ( Site 0102), Harbin, Heilongjiang, China
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Toray Industries, Inc
- Target Recruit Count
- 187
- Registration Number
- NCT03872947
- Locations
- 🇺🇸
HOAG Memorial Hospital Presbyterian, Newport, California, United States
🇺🇸Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Northwest Cancer Specialists, Portland, Oregon, United States
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 102
- Registration Number
- NCT03837977
- Locations
- 🇬🇧
The Beaston West of Scotland Cancer Center, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
🇬🇧Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.